<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment-emergent central sleep apnea
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment-emergent central sleep apnea
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment-emergent central sleep apnea
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susmita Chowdhuri, MD, MS, FAASM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sairam Parthasarathy, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            M Safwan Badr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H18678839">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment-emergent central sleep apnea (CSA), previously referred to as complex sleep apnea, is detected in approximately 5 to 15 percent of patients who undergo positive airway pressure (PAP) titration for obstructive sleep apnea (OSA).
        </p>
        <p>
         In more than half of cases, treatment-emergent CSA is a transient phenomenon that resolves within the first few months of PAP. Less commonly, the abnormality is persistent and requires a change in mode of ventilation.
        </p>
        <p>
         The epidemiology, pathogenesis, clinical presentation, clinical findings, diagnostic criteria, and management of treatment-emergent CSA are reviewed here. The diagnosis and management of OSA and central sleep apnea are described separately. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7695.html" rel="external">
          "Obstructive sleep apnea: Overview of management in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7701.html" rel="external">
          "Central sleep apnea: Risk factors, clinical presentation, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7675.html" rel="external">
          "Central sleep apnea: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18678846">
         <span class="h1">
          PREVALENCE AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk factors for treatment-emergent central sleep apnea (CSA) are not well understood, and there is wide variability in the reported incidence depending upon the study and the population. In a large prospective study, the prevalence during the first night with stable continuous positive airway pressure (CPAP) was 12 percent [
         <a href="#rid1">
          1
         </a>
         ]. Smaller studies have reported an incidence ranging from 5 to 20 percent [
         <a href="#rid2">
          2
         </a>
         ]. The incidence tends to be higher in studies using split-night versus full-night PAP titration.
        </p>
        <p>
         Factors associated with an increased likelihood of treatment-emergent CSA in small studies include  (
         <a class="graphic graphic_table graphicRef84027" href="/z/d/graphic/84027.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Male sex [
         <a href="#rid3">
          3-5
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older age [
         <a href="#rid1">
          1,6
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comorbid heart failure or coronary artery disease [
         <a href="#rid2">
          2,4,7
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe obstructive sleep apnea (OSA) [
         <a href="#rid8">
          8
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of a mixture of obstructive, mixed, and central apneas during initial polysomnography [
         <a href="#rid1">
          1,4,8-10
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher arousal index on baseline polysomnography [
         <a href="#rid1">
          1,4
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of higher levels of CPAP (ie, over-titration) [
         <a href="#rid5">
          5,11
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of bilevel PAP or a high-pressure support level [
         <a href="#rid5">
          5,12
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High altitude [
         <a href="#rid13">
          13
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral breathing [
         <a href="#rid14">
          14
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opioid use [
         <a href="#rid5">
          5,15
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Supine sleep position [
         <a href="#rid16">
          16,17
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated nasal resistance with CPAP intolerance [
         <a href="#rid18">
          18
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18678853">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whether or not treatment-emergent central sleep apnea (CSA) and obstructive sleep apnea (OSA) are separate disorders is controversial [
         <a href="#rid3">
          3,14,19
         </a>
         ]. Treatment-emergent CSA shares similar pathophysiology with OSA and CSA but is a dynamic process, which often resolves spontaneously with ongoing positive pressure therapy [
         <a href="#rid6">
          6,20,21
         </a>
         ].
        </p>
        <p>
         There are numerous potential mechanisms by which treatment of OSA may induce central apneas, including the following [
         <a href="#rid14">
          14,20
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Loop gain
         </strong>
         – Loop gain refers to the ratio of a corrective ventilatory response to a disturbance. If the response exceeds the disturbance (ie, loop gain &gt;1), then self-sustaining periodic breathing with central apneas may result. Patients with OSA frequently exhibit "high loop gain" or "ventilatory instability" at baseline, which is augmented by PAP therapy. As a result, minor disturbances (eg, arousals from sleep) result in an exuberant corrective ventilatory response (ie, hyperpnea) and then central apnea if the arterial carbon dioxide tension (PaCO
         <sub>
          2
         </sub>
         ) falls below the apneic threshold. The central apnea, in turn, prompts a reciprocal corrective response, establishing a pattern of periodic breathing. High loop gain is more prevalent in patients with severe OSA than those with mild OSA [
         <a href="#rid8">
          8
         </a>
         ], as well as in patients who receive BPAP rather than CPAP [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positive airway pressure (PAP)
         </strong>
         – PAP therapy relieves repetitive upper airway obstruction, which increases the elimination of CO
         <sub>
          2
         </sub>
         , lowers the PaCO
         <sub>
          2
         </sub>
         , and induces treatment-associated central apnea if the PaCO
         <sub>
          2
         </sub>
         falls below the apneic threshold [
         <a href="#rid8">
          8,22-24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intermittent hypoxia
         </strong>
         – Acute intermittent hypoxia is associated with increased chemoreflex sensitivity and increased propensity to develop central apnea [
         <a href="#rid25">
          25
         </a>
         ]. This may explain the higher likelihood of developing treatment-emergent CSA during split-night versus full-night PAP titration studies. Likewise, chronic intermittent hypoxia, as in OSA, is associated with increased peripheral chemoreflex activity. Accordingly, patients with OSA are more susceptible to the development of hypocapnic central apnea secondary to increased CO
         <sub>
          2
         </sub>
         chemoreflex sensitivity relative to healthy control subjects. Treatment with nasal CPAP for three months was associated with decreased chemoreflex sensitivity and decreased propensity to develop central apnea [
         <a href="#rid26">
          26
         </a>
         ]. This may also explain the finding that treatment-emergent CSA resolved after a few months of PAP therapy in a majority of the patients [
         <a href="#rid6">
          6,15,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Air leak
         </strong>
         – Air leak during PAP titration may be associated with the development of acute central apnea, owing to CO
         <sub>
          2
         </sub>
         washout from the mask and the anatomic dead space [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stretch receptor activation
         </strong>
         – PAP therapy activates stretch receptors, which inhibits central respiratory output and causes central apnea [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         While these mechanisms directly link PAP therapy to the development of central apneas, it is important to realize that other factors may contribute in some situations. These include loss of the wakefulness stimulus to breath during sleep [
         <a href="#rid28">
          28
         </a>
         ], baseline hypocapnia due to heart failure [
         <a href="#rid29">
          29
         </a>
         ], reduced drive to breathe due to opioids or high altitude [
         <a href="#rid13">
          13
         </a>
         ], and concomitant hypoxia [
         <a href="#rid8">
          8
         </a>
         ]. Moreover, OSA itself increases the propensity to central apneas in association with a higher loop gain [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16270696">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H9126221">
         <span class="h2">
          Presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment-emergent central apneas typically come to medical attention as a polysomnographic finding during the initial in-laboratory titration of continuous positive airway pressure (CPAP) therapy (or bilevel positive airway pressure without a backup respiratory rate) for obstructive sleep apnea (OSA). Specifically, central apneas and hypopneas emerge or increase during the titration, which prevent the apnea-hypopnea index (AHI) from normalizing despite the disappearance of obstructive apneas and hypopneas. The treatment-emergent apneas almost invariably occur during non-rapid eye movement (NREM) sleep [
         <a href="#rid30">
          30-32
         </a>
         ] and may be increased during supine sleep [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Less commonly, treatment-emergent central apneas begin after several months of positive airway pressure (PAP) therapy [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9126308">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with an increased number of central apneas while being treated with PAP may remain asymptomatic or manifest symptoms and signs of disrupted sleep due to the central apneas and accompanying arousals. Only those with attributable symptoms are considered to have a disorder. The symptoms and signs may include excessive daytime sleepiness, poor subjective sleep quality, repetitive awakenings with or without a feeling of breathlessness, insomnia, fatigue, inattention, poor concentration, and moodiness. Resolution of these sleep-related symptoms with effective treatment would confirm relatedness to treatment-emergent CSA.
        </p>
        <p>
         Patients may also report symptoms related to recurrent oxyhemoglobin desaturation, including morning headaches and nocturnal angina. Some patients describe paroxysmal nocturnal dyspnea due to the compensatory hyperpnea that follows a central apnea.
        </p>
        <p>
         Snoring is not a typical finding because patients with treatment-emergent central apneas have had their recurrent upper airway obstruction alleviated by the PAP therapy.
        </p>
        <p class="headingAnchor" id="H9126315">
         <span class="h2">
          Examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no physical findings that are specific for treatment-emergent central apneas. However, most patients have physical features that are typical of patients with OSA, including obesity, a large neck circumference, and/or a crowded upper airway [
         <a href="#rid3">
          3,30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Physical examination'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4855760">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment-emergent central sleep apnea (CSA) is diagnosed when central apneas develop in patients with obstructive sleep apnea (OSA) after the application of continuous positive airway pressure (CPAP), and symptoms are attributable to the central apneas. No additional diagnostic testing is indicated or required beyond history and polysomnography.
        </p>
        <p>
         With the increased adoption of home sleep apnea testing (HSAT) and auto-titrating PAP devices for OSA, emergent CSA may be detected in the download from an auto-titrating PAP device as an elevated residual apnea-hypopnea index (AHI). This finding usually warrants further confirmatory evaluation by an in-laboratory polysomnography with PAP titration. (See
         <a class="medical medical_review" href="/z/d/html/97878.html" rel="external">
          "Downloading data from positive airway pressure devices in adults", section on 'Continuous PAP downloads'
         </a>
         .)
        </p>
        <p>
         Diagnostic criteria for treatment-emergent CSA according to the third edition of the International Classification of Sleep Disorders (ICSD-3) include all of the following [
         <a href="#rid32">
          32
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diagnostic polysomnography (or HSAT, usually confirmed by repeat polysomnography) shows ≥5 predominantly obstructive respiratory events (obstructive or mixed apneas, hypopneas, or respiratory effort-related arousals) per hour of sleep
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polysomnography during the use of positive airway pressure without a backup rate shows significant resolution of obstructive events and emergence or persistence of central apnea or central hypopnea with all of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Central apnea and central hypopnea index ≥5 per hour
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Number of central apneas and central hypopneas is ≥50 percent of the total number of apneas and hypopneas
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of at least one of the following symptoms or signs thought to be attributable to the central events:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sleepiness
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Difficulty initiating or maintaining sleep, frequent awakenings, or nonrestorative sleep
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Awakening short of breath
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Witnessed apneas
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The CSA is not better explained by another CSA disorder, such as CSA with Cheyne-Stokes breathing or CSA due to a medication or substance
        </p>
        <p>
        </p>
        <p>
         It is important to note that contributing factors such as mask leak or excessive CPAP pressures should be addressed on the PAP titration study prior to making a diagnosis of treatment-emergent CSA. Downloaded data from PAP devices may not accurately detect central events, and in such cases, the presence of central apneas should be verified on polysomnography prior to making a diagnosis of treatment-emergent CSA.
        </p>
        <p>
         Obstructive apneas, central apneas, mixed apneas, hypopneas, and the AHI are defined separately. (See
         <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">
          "Polysomnography in the evaluation of sleep-disordered breathing in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16270712">
         <span class="h1">
          NATURAL HISTORY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The natural history of treatment-emergent central sleep apnea (CSA) is not well defined prospectively. In observational studies, central events resolve spontaneously in 50 to 85 percent of patients who return for repeat polysomnography after several months of continuous positive airway pressure (CPAP) therapy [
         <a href="#rid1">
          1,2,6,14,15,19,21,33
         </a>
         ]. Similar numbers were reported in the CPAP arm of a small, randomized trial, in which approximately two-thirds of patients with treatment-emergent CSA achieved an apnea-hypopnea index (AHI) &lt;10 per hour after 90 days of CPAP therapy [
         <a href="#rid34">
          34
         </a>
         ]. This proportion improved to 73 percent when limited to patients who were adherent with therapy.
        </p>
        <p>
         Patients with treatment-emergent CSA appear to be at increased risk for adverse outcomes. In one large database study, patients with treatment-emergent CSA at week 1 or 13 of PAP therapy were at higher risk of early PAP termination [
         <a href="#rid6">
          6
         </a>
         ]. In a separate study, treatment-emergent CSA was associated with higher rates of postoperative complications, including unplanned intensive care admissions, 30-day readmission rate, and mortality rate [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18678874">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of treatment-emergent central sleep apnea (CSA) is controversial, and treatment recommendations are derived from clinical experience, small observational studies, and a limited number of clinical trials. Since many patients improve spontaneously after several months of continuous positive airway pressure (CPAP) therapy, expectant management with CPAP is appropriate in most cases.
        </p>
        <p>
         In patients who do not improve, options include changing the mode of positive airway pressure to either adaptive servo-ventilation (ASV) or bilevel positive airway pressure (BPAP) with a backup rate. If these modes are unavailable or too costly, however, continuing CPAP is preferable to discontinuing the treatment of obstructive sleep apnea (OSA) altogether.
        </p>
        <p class="headingAnchor" id="H13424170">
         <span class="h2">
          Expectant management with CPAP
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with treatment-emergent CSA, we suggest expectant management with CPAP therapy, rather than making an immediate change in therapy. We perform a repeat clinical evaluation and diagnostic sleep test in two to three months after the initial study. The test should be performed with patients wearing their device.
        </p>
        <p>
         This approach is supported by retrospective and limited prospective data showing that central apneas improve or resolve spontaneously in approximately two-thirds of patients who continue CPAP for 90 days [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="local">
          'Natural history'
         </a>
         above.)
        </p>
        <p>
         As part of expectant management, patients should be evaluated for comorbidities and medications that may increase the likelihood of central apneas. This includes optimization of the heart failure regimen in patients with symptomatic heart failure and rigorous assessment of the need for continuing opioid therapy in patients taking opioids.
        </p>
        <p>
         Predictors of persistent central apneas on continued CPAP are not well defined, and clinical symptoms may or may not be present. Repeat polysomnography or home sleep apnea testing (HSAT) is therefore required after two to three months to determine whether further changes are necessary, considering that limited data suggest that ASV or BPAP with a backup rate may be more effective in controlling CPAP-emergent central apneas [
         <a href="#rid34">
          34,36
         </a>
         ]. Clinical symptoms and adherence should be reassessed at this time as well.
        </p>
        <p>
         The decision to continue CPAP therapy or change to an alternative mode of ventilation should be made based upon the persistence of CPAP-emergent central apneas, the stability of the patient’s medical condition (such as coexistent heart failure), and the severity of sleep-related symptoms. Data in heart failure patients with CSA suggest that improvements in left ventricular ejection fraction (EF) and transplant-free survival are dependent upon adequate suppression of central apneas [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1043268267">
         <span class="h2">
          Alternative modes of ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         ASV and BPAP with a backup rate are alternative modes of ventilation in patients with persistent central apneas on CPAP. The data reviewed below suggest that both ASV and BPAP with a backup respiratory rate decrease the frequency of obstructive and central apnea and hypopneas, but ASV may have a slightly larger magnitude of effect. In addition, limited longer-term data suggest that re-emergence of central events may be of concern with BPAP but not ASV [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18678881">
         <span class="h3">
          Adaptive servo-ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Small clinical trials have consistently shown that the apnea-hypopnea index (AHI) is also lowered by ASV in patients with treatment-emergent CSA, with the AHI typically improving to &lt;10 events per hour both acutely and after several months of therapy in a large majority of patients [
         <a href="#rid7">
          7,37-41
         </a>
         ]. Our confidence in this evidence is limited, however, because it consists of small trials that measured primarily physiological outcomes rather than patient-important outcomes. Notably, most of these trials were funded by the makers of the PAP device being studied. Moreover, ASV devices are considerably more expensive than CPAP devices.
        </p>
        <p>
         While ASV may be more effective at reducing the AHI compared with CPAP, the clinical relevance of this advantage is not yet clear [
         <a href="#rid34">
          34,42
         </a>
         ]. In a multicenter trial, 66 patients with treatment-emergent CSA and a residual central apnea index (CAI) &gt;10 events per hour during the CPAP titration study were randomly assigned to ASV or CPAP therapy for 90 days [
         <a href="#rid34">
          34
         </a>
         ]. There were no significant differences in baseline clinical characteristics between the two groups, although more patients in the CPAP arm were male (91 versus 79 percent) and had heart failure (15 versus 3 percent). Six patients failed to complete the study, and the adherence rate (defined as use of the study device for ≥4 hours per night and on ≥70 percent of the nights during the study) in the remaining patients was 60 percent. Results included the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After 90 days of therapy, the AHI was lower in patients treated with ASV versus CPAP (4.4 versus 9.9 events per hour, p = 0.002), but the absolute difference of 5.5 events per hour was lower than the prespecified clinically relevant difference of 10 events per hour.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The proportion of patients who achieved an AHI &lt;10 events per hour was greater for ASV (90 versus 65 percent). An analysis in adherent patients yielded similar results (94 versus 74 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients in both groups had improved Epworth Sleepiness Scale (ESS) scores and minimal change in measures of quality of life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No baseline clinical or polysomnographic characteristics could be identified that predicted lack of improvement on CPAP.
        </p>
        <p>
        </p>
        <p>
         ASV provides a varying amount of inspiratory pressure superimposed on a low level of CPAP, with a backup respiratory rate [
         <a href="#rid39">
          39,43-46
         </a>
         ]. The magnitude of the inspiratory pressure provided by the device is reciprocal to changes in peak flow, determined over a three- to four-minute moving window  (
         <a class="graphic graphic_figure graphicRef84026" href="/z/d/graphic/84026.html" rel="external">
          figure 1
         </a>
         ). Thus, peak flows that are lower than the average peak flow induce an increase in the amount of inspiratory pressure; conversely, peak flows that are higher than the average peak flow induce a decrease in the amount of inspiratory pressure. The backup respiratory rate can be set automatically by the device or manually and is an important aspect of ASV [
         <a href="#rid41">
          41,46
         </a>
         ].
        </p>
        <p>
         Of note, ASV should be avoided in patients with CSA associated with heart failure with reduced EF. This is based on results of SERVE-HF, a randomized trial of ASV versus standard medical therapy in patients with predominantly CSA due to symptomatic heart failure and a low EF (≤45 percent) in which ASV was associated with a 6 percent absolute increase in all-cause mortality and cardiovascular mortality compared with standard medical therapy [
         <a href="#rid47">
          47
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/7675.html" rel="external">
          "Central sleep apnea: Treatment", section on 'Patients with ejection fraction ≤45 percent'
         </a>
         ). For this reason, ASV should be avoided in patients with left ventricular EF ≤45 percent. We recommend obtaining an echocardiogram before prescribing ASV to patients with treatment-emergent CSA to verify that EF is &gt;45 percent. Moreover, in an industry-sponsored randomized controlled cross-over trial of patients with treatment-emergent CSA with preserved left ventricular EF, there were significant differences in minute ventilation and sleep architecture while receiving ASV therapy from various available devices [
         <a href="#rid48">
          48
         </a>
         ]. In this study, higher minute ventilation was associated with small but statistically nonsignificant prolongation of QT interval, suggesting that there may be device-specific rather than ASV class-specific effects that may have been responsible for the observed increased cardiovascular mortality in the SERVE-HF trial. An observational study that conducted phenotype cluster analysis suggested that patients with heart failure with mildly reduced EF and both central and obstructive sleep apnea may have better prognosis when adherent to ASV therapy than when nonadherent to such therapy [
         <a href="#rid49">
          49
         </a>
         ]. However, this observational study suggests association and not causation. Awaited results of the ADVENT-HF study, which addresses ASV treatment in both treatment-emergent CSA and CSA with Cheyne-Stokes breathing, could provide more definitive answers [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7682.html" rel="external">
          "Sleep-disordered breathing in heart failure"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18678888">
         <span class="h3">
          BPAP with a backup respiratory rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         BPAP with a backup rate can also lower the AHI compared with levels during CPAP initiation in patients with treatment-emergent CSA, at least initially [
         <a href="#rid31">
          31,39,43
         </a>
         ].
        </p>
        <p>
         Small trials have demonstrated that BPAP with a backup rate and ASV perform similarly, although re-emergence of central apneas might be of concern with BPAP with a backup rate:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial that included nine patients with treatment-emergent CSA, ASV reduced the AHI from 52 to 1 event per hour, while BPAP with a backup rate reduced the AHI from 52 to 6 events per hour [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a larger randomized trial that included 30 patients with treatment-emergent CSA, both ASV and BPAP, with a backup rate just below the average sleep-related respiratory rate, reduced the first-night AHI (28 to 9 events per hour and 29 to 9 events per hour, respectively); however, there was re-emergence of central events in the BPAP group after six weeks [
         <a href="#rid37">
          37
         </a>
         ]. This observation requires further study and independent confirmation, given that the pathophysiologic mechanisms of recurrence with BPAP, but not with ASV, with backup rate remains unexplained if patients were adherent to therapy.
        </p>
        <p>
        </p>
        <p>
         BPAP delivers positive airway pressure at different, but fixed, levels during inspiration and expiration. The level during inspiration is called the inspiratory positive airway pressure (IPAP) and the level during expiration is called the expiratory positive airway pressure (EPAP). BPAP has two major effects. First, it splints the upper airway open. Second, it increases alveolar ventilation by augmenting the tidal volume. The tidal volume is directly related to the difference between the IPAP and EPAP ("pressure assist"). As an example, the tidal volume is greater when the IPAP is set at 15 cm H
         <sub>
          2
         </sub>
         O and the EPAP at 5 cm H
         <sub>
          2
         </sub>
         O (difference of 10 cm H
         <sub>
          2
         </sub>
         O), than when the IPAP is set at 10 cm H
         <sub>
          2
         </sub>
         O and the EPAP at 5 cm H
         <sub>
          2
         </sub>
         O (difference of 5 cm H
         <sub>
          2
         </sub>
         O). (See
         <a class="medical medical_review" href="/z/d/html/7677.html" rel="external">
          "Titration of positive airway pressure therapy for adults with obstructive sleep apnea", section on 'Bilevel positive airway pressure, spontaneous mode (BPAP-S)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2086821776">
         <span class="h2">
          Modes to avoid
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast to BPAP with a backup rate, BPAP without a backup rate does
         <strong>
          not
         </strong>
         decrease the AHI during BPAP compared with during the initiation of CPAP in patients with treatment-emergent CSA, and it may even worsen the AHI.
        </p>
        <p>
         This was suggested by a retrospective cohort study of 63 patients with treatment-emergent CSA that found that BPAP without a backup rate increased the AHI from 30 to 52 events per hour [
         <a href="#rid31">
          31
         </a>
         ] and supported by indirect evidence from a retrospective cohort study of 95 patients with various types of central apnea that found that BPAP without a backup rate was more likely to be associated with increased rather than decreased central events [
         <a href="#rid12">
          12
         </a>
         ]. Therefore, BPAP without a backup rate is not recommended in patients with treatment-emergent CSA [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H39874336">
         <span class="h2">
          Other potential therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supplemental nocturnal oxygen has been tried with some success in patients with CSA due to heart failure [
         <a href="#rid52">
          52,53
         </a>
         ], providing potential rationale for its use in treatment-emergent CSA. The proposed mechanism of action is via a reduction in loop gain with resultant amelioration of CSA [
         <a href="#rid54">
          54,55
         </a>
         ]. However, there are no controlled trials of oxygen alone or in conjunction with PAP in patients with treatment-emergent CSA.
        </p>
        <p class="headingAnchor" id="H4280658508">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113310.html" rel="external">
          "Society guideline links: Sleep-related breathing disorders in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18679170">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Persistent or emergent central apneas are detected in approximately 5 to 15 percent of patients who undergo positive airway pressure (PAP) titration for obstructive sleep apnea (OSA). (See
         <a class="local">
          'Prevalence and risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Treatment-emergent central apneas are a polysomnographic finding during the initial in-laboratory titration of continuous positive airway pressure (CPAP) therapy (or bilevel positive airway pressure [BPAP] without a backup respiratory rate) for OSA. (See
         <a class="local">
          'Presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Symptoms of disrupted sleep (eg, excessive daytime sleepiness) may arise due to the central apneas and accompanying arousals. Patients may also report symptoms related to recurrent oxyhemoglobin desaturation. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Diagnostic criteria for treatment-emergent central sleep apnea (CSA) include the following (see
         <a class="local">
          'Diagnosis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients must have confirmed OSA, defined as predominantly obstructive respiratory events occurring at a frequency of ≥5 events per hour of sleep.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Upon exposure to positive airway pressure without a backup respiratory rate, all of the following must be present: significant resolution of obstructive events; central hypopnea index ≥5 events per hour; central apneas and hypopneas make up ≥50 percent of the total number of apneas and hypopneas; and symptoms of excessive daytime sleepiness or disrupted sleep.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The central apneas emerging during positive airway pressure therapy are not better explained by another CSA disorder.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Natural history
         </strong>
         – Treatment-emergent CSA resolves spontaneously in approximately two-thirds of patients on continued CPAP therapy. (See
         <a class="local">
          'Natural history'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Expectant management
         </strong>
         – For patients with treatment-emergent CSA, we suggest continuing CPAP as initial therapy rather than switching to an alternative mode of ventilation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Patients should undergo repeat polysomnography or home sleep apnea testing (HSAT) while wearing their device in two to three months to determine whether central apneas have resolved. (See
         <a class="local">
          'Expectant management with CPAP'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Persistent central apneas
         </strong>
         – For most patients with persistent central apneas on CPAP, we suggest switching to adaptive servo-ventilation (ASV) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). ASV is contraindicated in patients with left ventricular ejection fraction (EF) ≤45 percent. We recommend obtaining an echocardiogram before prescribing ASV to patients with treatment-emergent CSA to verify that EF is &gt;45 percent. In situations in which ASV is not available, too expensive, or is contraindicated, BPAP with a backup rate is a reasonable alternative. If neither mode is available, continuing CPAP is preferable to discontinuing therapy altogether. (See
         <a class="local">
          'Alternative modes of ventilation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Modes to avoid
         </strong>
         – ASV should be avoided in patients with heart failure and a reduced ejection fraction (LVEF ≤45 percent), based on concerns that it may increase cardiovascular mortality when used to treat CSA in this patient population. (See
         <a class="medical medical_review" href="/z/d/html/7675.html" rel="external">
          "Central sleep apnea: Treatment", section on 'Patients with ejection fraction ≤45 percent'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         BPAP without a backup rate may be ineffective or harmful in patients with treatment-emergent CSA. (See
         <a class="local">
          'Modes to avoid'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Cassel W, Canisius S, Becker HF, et al. A prospective polysomnographic study on the evolution of complex sleep apnoea. Eur Respir J 2011; 38:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nigam G, Riaz M, Chang ET, Camacho M. Natural history of treatment-emergent central sleep apnea on positive airway pressure: A systematic review. Ann Thorac Med 2018; 13:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgenthaler TI, Kagramanov V, Hanak V, Decker PA. Complex sleep apnea syndrome: is it a unique clinical syndrome? Sleep 2006; 29:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehman S, Antic NA, Thompson C, et al. Central sleep apnea on commencement of continuous positive airway pressure in patients with a primary diagnosis of obstructive sleep apnea-hypopnea. J Clin Sleep Med 2007; 3:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moro M, Gannon K, Lovell K, et al. Clinical predictors of central sleep apnea evoked by positive airway pressure titration. Nat Sci Sleep 2016; 8:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu D, Armitstead J, Benjafield A, et al. Trajectories of Emergent Central Sleep Apnea During CPAP Therapy. Chest 2017; 152:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bitter T, Westerheide N, Hossain MS, et al. Complex sleep apnoea in congestive heart failure. Thorax 2011; 66:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Younes M, Ostrowski M, Thompson W, et al. Chemical control stability in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2001; 163:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pusalavidyasagar SS, Olson EJ, Gay PC, Morgenthaler TI. Treatment of complex sleep apnea syndrome: a retrospective comparative review. Sleep Med 2006; 7:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavsic K, Herkenrath S, Treml M, et al. Mixed Apnea Metrics in Obstructive Sleep Apnea Predict Treatment-Emergent Central Sleep Apnea. Am J Respir Crit Care Med 2021; 203:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckle P, Millar T, Kryger M. The effect of short-term nasal CPAP on Cheyne-Stokes respiration in congestive heart failure. Chest 1992; 102:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson KG, Johnson DC. Bilevel positive airway pressure worsens central apneas during sleep. Chest 2005; 128:2141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nussbaumer-Ochsner Y, Schuepfer N, Ulrich S, Bloch KE. Exacerbation of sleep apnoea by frequent central events in patients with the obstructive sleep apnoea syndrome at altitude: a randomised trial. Thorax 2010; 65:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhotra A, Bertisch S, Wellman A. Complex sleep apnea: it isn't really a disease. J Clin Sleep Med 2008; 4:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javaheri S, Smith J, Chung E. The prevalence and natural history of complex sleep apnea. J Clin Sleep Med 2009; 5:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambrogio C, Lowman X, Kuo M, et al. Sleep and non-invasive ventilation in patients with chronic respiratory insufficiency. Intensive Care Med 2009; 35:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yaegashi H, Fujimoto K, Abe H, et al. Characteristics of Japanese patients with complex sleep apnea syndrome: a retrospective comparison with obstructive sleep apnea syndrome. Intern Med 2009; 48:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakazaki C, Noda A, Yasuda Y, et al. Continuous positive airway pressure intolerance associated with elevated nasal resistance is possible mechanism of complex sleep apnea syndrome. Sleep Breath 2012; 16:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gay PC. Complex sleep apnea: it really is a disease. J Clin Sleep Med 2008; 4:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeineddine S, Badr MS. Treatment-Emergent Central Apnea: Physiologic Mechanisms Informing Clinical Practice. Chest 2021; 159:2449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuzniar TJ, Pusalavidyasagar S, Gay PC, Morgenthaler TI. Natural course of complex sleep apnea--a retrospective study. Sleep Breath 2008; 12:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meza S, Mendez M, Ostrowski M, Younes M. Susceptibility to periodic breathing with assisted ventilation during sleep in normal subjects. J Appl Physiol (1985) 1998; 85:1929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dempsey JA. Crossing the apnoeic threshold: causes and consequences. Exp Physiol 2005; 90:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skatrud JB, Dempsey JA, Badr S, Begle RL. Effect of airway impedance on CO2 retention and respiratory muscle activity during NREM sleep. J Appl Physiol (1985) 1988; 65:1676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chowdhuri S, Shanidze I, Pierchala L, et al. Effect of episodic hypoxia on the susceptibility to hypocapnic central apnea during NREM sleep. J Appl Physiol (1985) 2010; 108:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salloum A, Rowley JA, Mateika JH, et al. Increased propensity for central apnea in patients with obstructive sleep apnea: effect of nasal continuous positive airway pressure. Am J Respir Crit Care Med 2010; 181:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montesi SB, Bakker JP, Macdonald M, et al. Air leak during CPAP titration as a risk factor for central apnea. J Clin Sleep Med 2013; 9:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khoo MC, Gottschalk A, Pack AI. Sleep-induced periodic breathing and apnea: a theoretical study. J Appl Physiol (1985) 1991; 70:2014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie A, Skatrud JB, Puleo DS, et al. Apnea-hypopnea threshold for CO2 in patients with congestive heart failure. Am J Respir Crit Care Med 2002; 165:1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas RJ, Terzano MG, Parrino L, Weiss JW. Obstructive sleep-disordered breathing with a dominant cyclic alternating pattern--a recognizable polysomnographic variant with practical clinical implications. Sleep 2004; 27:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allam JS, Olson EJ, Gay PC, Morgenthaler TI. Efficacy of adaptive servoventilation in treatment of complex and central sleep apnea syndromes. Chest 2007; 132:1839.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed, text revision, American Academy of Sleep Medicine, 2023.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dernaika T, Tawk M, Nazir S, et al. The significance and outcome of continuous positive airway pressure-related central sleep apnea during split-night sleep studies. Chest 2007; 132:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgenthaler TI, Kuzniar TJ, Wolfe LF, et al. The complex sleep apnea resolution study: a prospective randomized controlled trial of continuous positive airway pressure versus adaptive servoventilation therapy. Sleep 2014; 37:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barman RA, Fields AR, Eells AJ, et al. Postoperative outcomes in patients with treatment-emergent central sleep apnea: a case series. J Anesth 2020; 34:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arzt M, Floras JS, Logan AG, et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 2007; 115:3173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dellweg D, Kerl J, Hoehn E, et al. Randomized controlled trial of noninvasive positive pressure ventilation (NPPV) versus servoventilation in patients with CPAP-induced central sleep apnea (complex sleep apnea). Sleep 2013; 36:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westhoff M, Arzt M, Litterst P. Prevalence and treatment of central sleep apnoea emerging after initiation of continuous positive airway pressure in patients with obstructive sleep apnoea without evidence of heart failure. Sleep Breath 2012; 16:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgenthaler TI, Gay PC, Gordon N, Brown LK. Adaptive servoventilation versus noninvasive positive pressure ventilation for central, mixed, and complex sleep apnea syndromes. Sleep 2007; 30:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Randerath WJ, Galetke W, Kenter M, et al. Combined adaptive servo-ventilation and automatic positive airway pressure (anticyclic modulated ventilation) in co-existing obstructive and central sleep apnea syndrome and periodic breathing. Sleep Med 2009; 10:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javaheri S, Goetting MG, Khayat R, et al. The performance of two automatic servo-ventilation devices in the treatment of central sleep apnea. Sleep 2011; 34:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orr J, Javaheri S, Malhotra A. Comparative effectiveness research in complex sleep apnea. Sleep 2014; 37:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teschler H, Döhring J, Wang YM, Berthon-Jones M. Adaptive pressure support servo-ventilation: a novel treatment for Cheyne-Stokes respiration in heart failure. Am J Respir Crit Care Med 2001; 164:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arzt M, Wensel R, Montalvan S, et al. Effects of dynamic bilevel positive airway pressure support on central sleep apnea in men with heart failure. Chest 2008; 134:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pepperell JC, Maskell NA, Jones DR, et al. A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure. Am J Respir Crit Care Med 2003; 168:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonescu-Turcu A, Parthasarathy S. CPAP and bi-level PAP therapy: new and established roles. Respir Care 2010; 55:1216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med 2015; 373:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knitter J, Bailey OF, Poongkunran C, et al. Comparison of Physiological Performance of Four Adaptive Servo Ventilation Devices in Patients with Complex Sleep Apnea. Am J Respir Crit Care Med 2019; 199:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamisier R, Damy T, Bailly S, et al. FACE study: 2-year follow-up of adaptive servo-ventilation for sleep-disordered breathing in a chronic heart failure cohort. Sleep Med 2024; 113:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyons OD, Floras JS, Logan AG, et al. Design of the effect of adaptive servo-ventilation on survival and cardiovascular hospital admissions in patients with heart failure and sleep apnoea: the ADVENT-HF trial. Eur J Heart Fail 2017; 19:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuźniar TJ, Kasibowska-Kuźniar K, Freedom T. Trials of bilevel positive airway pressure - spontaneous in patients with complex sleep apnoea. Pneumonol Alergol Pol 2012; 80:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bordier P, Orazio S, Hofmann P, et al. Short- and long-term effects of nocturnal oxygen therapy on sleep apnea in chronic heart failure. Sleep Breath 2015; 19:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sasayama S, Izumi T, Seino Y, et al. Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-stokes respiration. Circ J 2006; 70:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeineddine S, Rowley JA, Chowdhuri S. Oxygen Therapy in Sleep-Disordered Breathing. Chest 2021; 160:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rastogi R, Badr MS, Ahmed A, Chowdhuri S. Amelioration of sleep-disordered breathing with supplemental oxygen in older adults. J Appl Physiol (1985) 2020; 129:1441.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14911 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21464115" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A prospective polysomnographic study on the evolution of complex sleep apnoea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29675059" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Natural history of treatment-emergent central sleep apnea on positive airway pressure: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17040008" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Complex sleep apnea syndrome: is it a unique clinical syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17803008" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Central sleep apnea on commencement of continuous positive airway pressure in patients with a primary diagnosis of obstructive sleep apnea-hypopnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27555802" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Clinical predictors of central sleep apnea evoked by positive airway pressure titration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28629918" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Trajectories of Emergent Central Sleep Apnea During CPAP Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21393364" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Complex sleep apnoea in congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11316657" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Chemical control stability in patients with obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16931153" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Treatment of complex sleep apnea syndrome: a retrospective comparative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33233936" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mixed Apnea Metrics in Obstructive Sleep Apnea Predict Treatment-Emergent Central Sleep Apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1623779" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The effect of short-term nasal CPAP on Cheyne-Stokes respiration in congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16236867" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Bilevel positive airway pressure worsens central apneas during sleep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20435865" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Exacerbation of sleep apnoea by frequent central events in patients with the obstructive sleep apnoea syndrome at altitude: a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18853695" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Complex sleep apnea: it isn't really a disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19960639" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The prevalence and natural history of complex sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18795255" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Sleep and non-invasive ventilation in patients with chronic respiratory insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19293541" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Characteristics of Japanese patients with complex sleep apnea syndrome: a retrospective comparison with obstructive sleep apnea syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21830062" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Continuous positive airway pressure intolerance associated with elevated nasal resistance is possible mechanism of complex sleep apnea syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18853694" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Complex sleep apnea: it really is a disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33497650" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Treatment-Emergent Central Apnea: Physiologic Mechanisms Informing Clinical Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17874254" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Natural course of complex sleep apnea--a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9804601" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Susceptibility to periodic breathing with assisted ventilation during sleep in normal subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15572458" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Crossing the apnoeic threshold: causes and consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3141362" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Effect of airway impedance on CO2 retention and respiratory muscle activity during NREM sleep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19940101" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Effect of episodic hypoxia on the susceptibility to hypocapnic central apnea during NREM sleep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19762565" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Increased propensity for central apnea in patients with obstructive sleep apnea: effect of nasal continuous positive airway pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24235901" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Air leak during CPAP titration as a risk factor for central apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1907602" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Sleep-induced periodic breathing and apnea: a theoretical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11991873" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Apnea-hypopnea threshold for CO2 in patients with congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15124715" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Obstructive sleep-disordered breathing with a dominant cyclic alternating pattern--a recognizable polysomnographic variant with practical clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18079219" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Efficacy of adaptive servoventilation in treatment of complex and central sleep apnea syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18079219" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Efficacy of adaptive servoventilation in treatment of complex and central sleep apnea syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17475636" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The significance and outcome of continuous positive airway pressure-related central sleep apnea during split-night sleep studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24790271" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The complex sleep apnea resolution study: a prospective randomized controlled trial of continuous positive airway pressure versus adaptive servoventilation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32696093" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Postoperative outcomes in patients with treatment-emergent central sleep apnea: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17562959" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23904676" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Randomized controlled trial of noninvasive positive pressure ventilation (NPPV) versus servoventilation in patients with CPAP-induced central sleep apnea (complex sleep apnea).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21347650" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Prevalence and treatment of central sleep apnoea emerging after initiation of continuous positive airway pressure in patients with obstructive sleep apnoea without evidence of heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17520791" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Adaptive servoventilation versus noninvasive positive pressure ventilation for central, mixed, and complex sleep apnea syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19303811" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Combined adaptive servo-ventilation and automatic positive airway pressure (anticyclic modulated ventilation) in co-existing obstructive and central sleep apnea syndrome and periodic breathing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22131607" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The performance of two automatic servo-ventilation devices in the treatment of central sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24790259" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Comparative effectiveness research in complex sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11520725" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Adaptive pressure support servo-ventilation: a novel treatment for Cheyne-Stokes respiration in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17951617" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Effects of dynamic bilevel positive airway pressure support on central sleep apnea in men with heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12928310" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20800002" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : CPAP and bi-level PAP therapy: new and established roles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26323938" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30605350" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Comparison of Physiological Performance of Four Adaptive Servo Ventilation Devices in Patients with Complex Sleep Apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37612192" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : FACE study: 2-year follow-up of adaptive servo-ventilation for sleep-disordered breathing in a chronic heart failure cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28371141" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Design of the effect of adaptive servo-ventilation on survival and cardiovascular hospital admissions in patients with heart failure and sleep apnoea: the ADVENT-HF trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22562273" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Trials of bilevel positive airway pressure - spontaneous in patients with complex sleep apnoea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24733715" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Short- and long-term effects of nocturnal oxygen therapy on sleep apnea in chronic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16377916" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-stokes respiration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33610579" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Oxygen Therapy in Sleep-Disordered Breathing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32969781" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Amelioration of sleep-disordered breathing with supplemental oxygen in older adults.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
